Home « About Novartis Oncology

At Novartis Oncology, our employees worldwide share a common mission: discover and develop innovative medicines to fight cancer. Headquartered in Florham Park, New Jersey, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer.

With more than 4,500 employees operating in over 50 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to improving and extending the lives of patients around the world.

We have a proven track record of providing new and improved cancer treatments and are continually discovering and developing new therapies that change lives. We are currently concentrating efforts on research platforms spanning discoveries in signal transduction inhibition, cytotoxic agents, antiangiogenesis, cell cyle/apoptosis, iron chelation, metastases and hormone therapy.

OPEN

OPEN is a visual expression of who we are and who we aspire to be as an organization. We value and strive for open listening, open dialogue and open collaboration with the healthcare community and our employees. For more information, please visit: http://www.novartisoncology.com.

Research

Innovative medicine begins with research. Our research approach is focused on discoveries within the study of genetics in cells and rational drug design. Drug design involves identifying the structure of a tumor and developing medicine that will specifically target it. We have over 120 collaborations with major biotech companies and over 280 with academic centers and have more than 150 clinical trials currently underway.

For more information about Novartis Institutes for Biomedical Research (NIBR) please visit http://www.nibr.com.

Once a promising medicine has been identified, we work with leading investigators and patient volunteers in countries around the world to study the safety and efficacy of the agent. In instances where an investigational drug shows efficacy in a difficult-to-treat population, we consider broadening access to these developmental medicines through an Expanded Access Program (EAP) and available regulatory mechanisms. These programs allow patients access to the experimental drug between the time of filing and application for approval with health authorities. Novartis Oncology was one of the first companies to offer truly global Expanded Access Programs.